Meeting
2023 ASCO Annual Meeting
Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.
Authors
Sarah P. Psutka
University of Washington, Fred Hutchinson Cancer Center, Seattle, WA
Sarah P. Psutka , Susan Veleber , Jonathan Siman , Sarah K. Holt , Samia Jannat , Jonathan L. Wright , Daniel W. Lin , John L. Gore , George Schade , Zachary Anton Annen , Heather Greenlee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04496219
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4590)
DOI
10.1200/JCO.2023.41.16_suppl.4590
Abstract #
4590
Poster Bd #
82
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer.
First Author: Borivoj Golijanin
Poster
2024 ASCO Genitourinary Cancers Symposium
Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.
First Author: Stephen B. Williams
Poster
2023 ASCO Annual Meeting
Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.
First Author: Jun J. Mao
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis